N/A N=13 What Have Been the Experiences of Female Survivors of Interpersonal Trauma on the Survive & Thrive Course
Interpersonal Trauma
Primary: Participants Experience of the Survive & Thrive Course - Themes — 12; 12; 13; 13 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=92 Dose Escalation Study Of Chinese Herbs In Osteoarthritis Of The Knee
Osteoarthritis of the Knee
Primary: ‡Pain Normalized Score — 3.3; 2.7 Units on a scale — p=0.05
N/A N=18 Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults
Attention Deficit Hyperactivity Disorder
Primary: Number of Participants That Tested High (6 or More Symptoms) for ADHD by Type Determined by Adult ADHD DSM IV-TR Checklist — 2; 5; 2 Participants
Phase 4 N=551 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery
Diphtheria · Hepatitis B · Acellular Pertussis
Primary: Number of Seroprotected Subjects Against Anti-diphtheria (Anti-D), Anti-tetanus (Anti-T), Anti-hepatitis B (Anti-HBs), Anti-poliovirus Type 1, Anti-poliovirus Type 2…
Phase 1 N=5 Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
Alcohol Drinking
Primary: Safety/Tolerability of Study Medication. — 0 participants
Phase 2 N=47 Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography
Breast Cancer
Primary: Change in Primary Tumor FFNP Uptake Before and After Estradiol Challenge as Measured by Percent Change in Standardized Uptake Value (SUV) — 11.0 percent change in SUV
Phase 2 N=16 Apremilast for Atopic Dermatitis - A Pilot Study in Adults
Atopic Dermatitis
Primary: Change in EASI Scores — -8.8; -8.2 units on a scale
Phase 4 N=34 PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
Diabetes Mellitus, Type 2
Primary: Change in Endogenous Glucose Production (EGP) — 2.03; 1.92; 1.55; 1.68 mg/kg.min
Phase 2 N=12 A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
Age-Related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) at Day 90. — -1.3; 2.7; 1.0; 3.3 ETDRS letters
Phase 3 N=462 Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea
Rosacea
Primary: Primary: Percentage of Treatment Success on Day 7 — 9.95; 10.36; 0 percentage of participants — p=<0.0001
Phase 3 N=336 Efficacy of Isradipine in Early Parkinson Disease
Parkinson Disease
Primary: Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score — 2.99; 3.26 score on a scale
N/A N=49 Variability In Hearing Aid Outcomes In Older Adults
Hearing Loss · Presbycusis
Primary: Speech Intelligibility Score — 69; 78 percentage of correct responses
Phase 2 N=135 Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis
Acidosis
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) and Number of Subjects Who Discontinued Study Drug Due to a TEAE — 14; 13; 9; 17 Participants
Phase 3 N=200 Safety of Switching From Rituximab to Ocrelizumab in MS Patients
Multiple Sclerosis
Primary: Proportion of Infusions With >= 1 IRR Between the Switching and Comparator Groups — 10; 14 percentage of infusions with IRRs — p=0.1996
Phase 2 N=80 Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
Multiple Myeloma · Primary Amyloidosis
Primary: Mean Symptom Severity Burden as Measured by MDASI Scores — 4.27; 4.26 score on a scale